Image is for illustration only. Actual medication labels identify the licensed compounding pharmacy that dispenses your prescription; DirectRxCare is not a pharmacy and does not compound medications.
- Needle-free daily tablet
- Dual GLP-1 and GIP receptor action
- Superior appetite suppression
- Improves insulin sensitivity
- Discreet and travel-friendly
- Physician-supervised dosing
Oral Tirzepatide
Needle-free dual-action support for weight loss
Important Information
- Already taking this medication? If you are not new to this treatment and need to continue at your current dose or move to a higher dose, you will need to provide supporting documentation (such as a recent prescription, pharmacy label, or provider records) showing you have recently been on it. Without this, your provider will start you at the beginning dose.
Compounded oral Tirzepatide tablets deliver dual GLP-1/GIP appetite control and metabolic support without injections.
Choose Your Plan
100% Money-Back Guarantee if Not Approved. Cancel anytime.
Please note: your medication will arrive in a bottle or vial with the dispensing pharmacy's branding and labeling — packaging may differ from the product image shown.
The Why
Why Oral Tirzepatide?
"Because the most powerful weight loss molecule shouldn't require a needle. Oral Tirzepatide brings dual GLP-1/GIP action to a once-daily tablet — maximum appetite control and metabolic support, zero injections."
"Oral Tirzepatide gave me everything I wanted from a GLP-1 without dealing with vials and syringes. Down 31 lbs in 4 months and the convenience is unbeatable."
David K.
Verified Patient
The Science Behind Oral Tirzepatide
Dual-pathway support in a needle-free format
2
Hormone pathways targeted
Daily
Once-a-day dosing
0
Needles required
How It Works
Oral tirzepatide uses the same dual GIP + GLP-1 approach as the injection, in a daily format for people who prefer not to inject.
Key Facts
- Tirzepatide activates both GIP and GLP-1 receptors, which work together on appetite and metabolism.
- Oral delivery of peptide medicines is an active, fast-growing area of research.
- Take exactly as directed by your provider for consistent absorption.
- Your provider will review your history to decide if this format is right for you.
Published Research
SURMOUNT-1 Trial
New England Journal of Medicine, 2022
In 2,539 adults with obesity, once-weekly tirzepatide produced average weight reductions of roughly 15% to 21% (depending on dose) over 72 weeks, versus about 3% with placebo.
Research summaries describe published studies of the active ingredient and are provided for education only. Compounded medications are not FDA-approved and were not the products studied. Individual results vary; a licensed provider will determine whether treatment is appropriate for you.
FAQ
